Vimta Labs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹112 Cr +9.8% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
VL

Vimta Labs Ltd

Q3 FY25Healthcare Services

Vimta Labs Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹90Cr
+23.3% YoY
+5.9% QoQ
Net profit
₹22Cr
+144.4% YoY
+46.7% QoQ
Margin
37%
+6 pp YoY
+2 pp QoQ

Based on Vimta Labs Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹598
Market cap₹2.7K Cr
P/E33.4

The short version

Q3 FY25 Revenue from Operations: ₹899 Mn. Q3 FY25 EBITDA: ₹343 Mn, a 39.4% year-on-year (YoY) increase.

From Vimta Labs Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY25 Revenue from Operations: ₹899 Mn
  • Q3 FY24 Revenue from Operations: ₹746 Mn
  • Year-on-Year (YoY) Revenue Growth: 21.1% (from Q3 FY24 to Q3 FY25)
  • Total Income Q3 FY25: ₹911 Mn (including other income)
  • EBITDA Q3 FY25: ₹343 Mn with a margin of 37.6% (39.4% YoY growth)
  • PAT Q3 FY25: ₹175 Mn with a margin of 19.2% (43.0% YoY growth)

2 more points from Vimta Labs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Q3 FY25 Capex: Rs 657 Mn (Page 6)
  • 9M FY25 Capex: Rs 958 Mn (Page 7)
  • Infrastructure growth over years shows increase in facility size from 500 ft² in 1984 to 600,000+ ft² in 2024 (Page 15), indicating ongoing expansions.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Vimta Labs Ltd said on order book & pipeline — free account, 30 seconds.

Vimta Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Vimta Labs Ltd Q3 FY25 results — key figures

Vimta Labs Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue9073+23.3%85+5.9%
Operating profit (EBITDA)3323+43.5%30+10%
Operating margin37%31%+6 pp35%+2 pp
Profit before tax2813+115.4%20+40%
Net profit (PAT)229+144.4%15+46.7%
EPS (₹)4.842.14+126.2%3.44+40.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹112 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • 3B Blackbio (Q3 FY25)

    Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…

  • Rainbow Childrens Medicare (Q3 FY25)

    Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

  • Dr Lal Pathlabs (Q3 FY25)

    Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…

  • Thyrocare Technologies (Q3 FY25)

    Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. Key concall takeaways from Thyrocare Technologies…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vimta Labs Ltd Q3 FY25 results?

Q3 FY25 Revenue from Operations: ₹899 Mn. Q3 FY25 EBITDA: ₹343 Mn, a 39.4% year-on-year (YoY) increase.

What is Vimta Labs Ltd share price analysis?

Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 33.4 with a market cap of ₹2,696 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vimta Labs Ltd planning capital expenditure?

Q3 FY25 Capex: Rs 657 Mn (Page 6) - 9M FY25 Capex: Rs 958 Mn (Page 7)

Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.